WO2009008888A1 - African swine virus polypeptides as vaccines and its therapeutic use thereof - Google Patents

African swine virus polypeptides as vaccines and its therapeutic use thereof Download PDF

Info

Publication number
WO2009008888A1
WO2009008888A1 PCT/US2007/073189 US2007073189W WO2009008888A1 WO 2009008888 A1 WO2009008888 A1 WO 2009008888A1 US 2007073189 W US2007073189 W US 2007073189W WO 2009008888 A1 WO2009008888 A1 WO 2009008888A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
leu
glu
arg
lys
Prior art date
Application number
PCT/US2007/073189
Other languages
French (fr)
Other versions
WO2009008888A8 (en
Inventor
Matthias Rath
Aleksandra Niedzwiecki
Original Assignee
Matthias Rath
Aleksandra Niedzwiecki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matthias Rath, Aleksandra Niedzwiecki filed Critical Matthias Rath
Priority to PCT/US2007/073189 priority Critical patent/WO2009008888A1/en
Publication of WO2009008888A1 publication Critical patent/WO2009008888A1/en
Publication of WO2009008888A8 publication Critical patent/WO2009008888A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • African Swine Virus Polypeptides as Vaccines and its therapeutic use thereof
  • the present invention generally relates to the use of selected polypeptides from African Swine virus for the prevention and therapy of African Swine infections as well as other infections, including immune deficiencies in mammals and humans.
  • African Swine fever is an endemic disease in sub-Saharan Africa and many other parts of the developing world. It is caused by the African Swine virus that primarily replicates in macrophages and monocytes leading to the impairment of the structure and function of the immune system of the infected organisms. Until now the African Swine epidemic continues to spread despite all efforts to contain it. Thus, there is an objective need for effective, safe and affordable preventive and therapeutic approaches, in particular for effective vaccines, to control and eventually eradicate this disease.
  • African Swine virus Since the characteristic feature of the African Swine virus is to impair the immune system and to cause immune deficiencies in its hosts the development of vaccines and other therapeutic approaches against the African Swine virus has implications for other immune deficiencies or diseases.
  • viruses are also known to cause immunodeficiency-like syndromes in humans, including cytomegalovirus, Epstein Barr Virus and others.
  • cytomegalovirus cytomegalovirus
  • Epstein Barr Virus a series of cases of so-called "idiopathic" immunodeficiencies have been documented that display CD4 + T-lymphocytopenia with opportunistic infections, but show no evidence of HIV infection (1). Since antibodies for the African Swine virus have been detected in humans, the possibility of human infection with the African Swine virus exists and may thus far have escaped any systematic screening. Thus, any preventive and therapeutic approach to African Swine fever can have far-reaching implications to control immune deficiency conditions in humans.
  • Synthetic oligopeptides prepared from African Swine virus proteins are effective in prevention, treatment and diagnosis of African Swine fever as well as for immune deficiencies in humans.
  • Oligopeptides are identified and selected by means of suitable algorithms from the known amino acid sequence of pathogenicity-mediating African Swine virus proteins. Subsequently, these oligopeptides are tested in vitro for their ability to decrease or completely block infection by the African Swine virus (prevention and therapy) or for their ability to raise antibodies to detect the virus (diagnosis). Ultimately, the successfully tested African Swine oligopeptides can be used in veterinary and clinical medicine.
  • the invention provides Oligopeptides selected from the group consisting of SEQ ID NO: 1 through SEQ ID NO: 111.
  • the oligopeptides sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by omitting one or several predetermined amino residues at the N -terminal 'end.
  • the oligopeptides sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by omitting one or several predetermined amino acid residues at the C-terminal end. In other embodiment, the oligopeptides sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by omitting one or several predetermined amino acid residues at the N-terminal and the C-terminal end.
  • the oligopeptides sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by substituting one or several predetermined amino acid residues within the given sequence without consideration of charge and polarity of the substitution residue.
  • oligopeptides sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by substituting one or several predetermined of the amino acid residues
  • the oligopeptides sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by omitting one or several predetermined amino acid residues within the given sequence.
  • the oligopeptides sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by repeating the oligopeptides sequence one or more times each of them covalently bound to one or several predetermined oligopeptides repeat(s) with linear topology or other peptidomemetic.
  • the oligopeptides sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by using cyclic oligopeptide topology instead of linear oligopeptide topology or other peptidomemetic.
  • the oligopeptides sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by repeating the oligopeptide sequence one or more times each of them covalently bound to one or more oligopeptides repeat(s) with cyclic topology or other cyclic peptidomemetic.
  • the oligopeptides sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 that contain two residues of the amino acid cystein are modified to form disulfide bonds thereby changing the secondary and tertiary structure of the oligopeptide as well as epitope formation.
  • modification of any of the sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 by a combination of two or more of the modifications of the invention is provided.
  • the preventive or therapeutic use of one or more of the oligopeptides identified as SEQ ID No: 1 through SEQ ID NO: 111 and/or modifications to the invention and/or other peptidomimetics to directly and competitively reduce or block infections by the African Swine virus.
  • the preventive or therapeutic use of one or more of the oligopeptides identified as SEQ ID No: 1 through SEQ ID NO: 111 and/or modifications to the invention and/or other peptidomimetics to indirectly reduce or block the metabolic action or interaction of African Swine virus by applying them as vaccines by subcutaneous application or in another acceptable way to stimulate a specific immune response which can partially or completely block infections by the African Swine virus.
  • the preventive or therapeutic use of one or more of the oligopeptides identified as SEQ ID No: 1 through SEQ ID NO: 111 and/or modifications to the invention and/or other peptidomimetics to directly and competitively reduce or block immune deficiencies.
  • the preventive or therapeutic use of one or more of the oligopeptides identified as SEQ ID No: 1 through SEQ ID NO: 111 and/or modifications to the invention and/or other peptidomimetics to indirectly reduce or block the metabolic action or interaction of African Swine virus by applying them as vaccines by subcutaneous application or in another acceptable way to stimulate a specific immune response which can partially or completely block immune deficiencies.
  • oligopeptides identified as SEQ ID No: 1 through SEQ ID NO: 111 and/or modifications to the invention to prevent or treat immune deficiencies in any other medically acceptable way.
  • oligopeptides identified as SEQ ID No: 1 through SEQ ID NO: 111 and/or modifications to the invention and/or other peptidomimetics for the prevention or therapy of infectious diseases.
  • oligopeptides identified as SEQ ID No: 1 through SEQ ID NO: 111 and/or modifications to the invention and/or other peptidomimetics for the prevention or therapy of diseases that may turn out to be caused or related to African Swine virus.
  • oligopeptides of claim 1-111 and/or modifications thereof identified as SEQ ID No: 1 through SEQ ID NO: 111 and/or other peptidomimetics of the invention for the production of specific antibodies for the diagnosis of a disease involving African Swine virus or the clinical monitoring of the progression or regression of this disease.
  • the use of one or more of the oligopeptides identified as SEQ ID No: 1 through SEQ ID NO: 111 and/or modifications to the invention and and/or other peptidomimetics for the production of specific antibodies for the diagnosis or the clinical monitoring of the progression or regression of immune deficiencies.
  • Figure 1 shows the antigenicity scores derived from and according to the Hopp-Woods hydrophylicity algorithm for the protein p54, a 183 amino acid long structural protein of the African Swine virus. Since p54 is involved in the pathogenesis of African Swine fever (2), interrupting this pathogenicity-mediating pathway will lead to a decrease or a complete block of infection by this virus.
  • the relative peaks of this algorithm defined as amino acid sequence regions of either high hydrophilic characteristics or sequence regions of higher hydrophilic characteristics in relation to adjacent amino acid sequences or in comparison to hydrophobic regions of the protein, represent the likely candidate sequence regions (oligopeptides) serving as epitopes (antigens) for antibody formation.
  • these defined oligopeptide sequences represent the likely region by which a protein interacts with other proteins and/or biological compounds in an organism, including those interactions that mediate infection or other forms of pathogenicity.
  • the African Swine virus is a particular virus the pathogenicity of which is largely determined by targeting the immune system of the host and disabling it.
  • the present invention describes the identification and production of preventive and therapeutic agents, which - among others - can be used as vaccines against African Swine fever with the following specific steps being taken:
  • the current invention also describes the application of the current invention for the diagnosis and treatment of immune deficiency conditions in mammals.
  • African Swine virus has been primarily detected in pigs and certain other animals, antibodies against the African Swine virus have also been found in humans (5).
  • the fact that there was no description of any finding of the African Swine virus in humans may thus be attributable to oversight or a lack of understanding for the significance of African Swine fever virus for the pathogenicity of immune deficiencies in humans.
  • the inventions described in this patent application can have far reaching implications not only for the control of African Swine fever but also for the control of other immunodeficiency diseases.
  • the main structural and/or pathogenicity mediating proteins of the African Swine virus are the following:

Abstract

The present invention relates to the use of selected polypeptides from African Swine virus for the prevention and therapy of African Swine infections as well as other infections, including immune deficiencies in mammals and humans.

Description

African Swine Virus Polypeptides as Vaccines and its therapeutic use thereof
By: Matthias Rath M.D., Aleksandra Niedzwiecki Ph.D.
FIELD OF THE INVENTION
The present invention generally relates to the use of selected polypeptides from African Swine virus for the prevention and therapy of African Swine infections as well as other infections, including immune deficiencies in mammals and humans.
BACKGROUND OF THE INVENTION
African Swine fever is an endemic disease in sub-Saharan Africa and many other parts of the developing world. It is caused by the African Swine virus that primarily replicates in macrophages and monocytes leading to the impairment of the structure and function of the immune system of the infected organisms. Until now the African Swine epidemic continues to spread despite all efforts to contain it. Thus, there is an objective need for effective, safe and affordable preventive and therapeutic approaches, in particular for effective vaccines, to control and eventually eradicate this disease.
Since the characteristic feature of the African Swine virus is to impair the immune system and to cause immune deficiencies in its hosts the development of vaccines and other therapeutic approaches against the African Swine virus has implications for other immune deficiencies or diseases. Several other viruses are also known to cause immunodeficiency-like syndromes in humans, including cytomegalovirus, Epstein Barr Virus and others. Moreover, a series of cases of so-called "idiopathic" immunodeficiencies have been documented that display CD4 + T-lymphocytopenia with opportunistic infections, but show no evidence of HIV infection (1). Since antibodies for the African Swine virus have been detected in humans, the possibility of human infection with the African Swine virus exists and may thus far have escaped any systematic screening. Thus, any preventive and therapeutic approach to African Swine fever can have far-reaching implications to control immune deficiency conditions in humans.
SUMMARY OF THE INVENTION
Synthetic oligopeptides prepared from African Swine virus proteins are effective in prevention, treatment and diagnosis of African Swine fever as well as for immune deficiencies in humans.
Oligopeptides are identified and selected by means of suitable algorithms from the known amino acid sequence of pathogenicity-mediating African Swine virus proteins. Subsequently, these oligopeptides are tested in vitro for their ability to decrease or completely block infection by the African Swine virus (prevention and therapy) or for their ability to raise antibodies to detect the virus (diagnosis). Ultimately, the successfully tested African Swine oligopeptides can be used in veterinary and clinical medicine.
Accordingly, in one aspect, the invention provides Oligopeptides selected from the group consisting of SEQ ID NO: 1 through SEQ ID NO: 111.
In one embodiment, the oligopeptides sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by omitting one or several predetermined amino residues at the N -terminal 'end.
In another embodiment, the oligopeptides sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by omitting one or several predetermined amino acid residues at the C-terminal end. In other embodiment, the oligopeptides sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by omitting one or several predetermined amino acid residues at the N-terminal and the C-terminal end.
In yet another embodiment, the oligopeptides sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by substituting one or several predetermined amino acid residues within the given sequence without consideration of charge and polarity of the substitution residue.
In still another embodiment, the oligopeptides sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by substituting one or several predetermined of the amino acid residues
In one embodiment, the oligopeptides sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by omitting one or several predetermined amino acid residues within the given sequence.
In another embodiment, the oligopeptides sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by repeating the oligopeptides sequence one or more times each of them covalently bound to one or several predetermined oligopeptides repeat(s) with linear topology or other peptidomemetic.
In yet other embodiment, the oligopeptides sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by using cyclic oligopeptide topology instead of linear oligopeptide topology or other peptidomemetic.
In yet another embodiment, the oligopeptides sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by repeating the oligopeptide sequence one or more times each of them covalently bound to one or more oligopeptides repeat(s) with cyclic topology or other cyclic peptidomemetic. In still another embodiment, the oligopeptides sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 that contain two residues of the amino acid cystein are modified to form disulfide bonds thereby changing the secondary and tertiary structure of the oligopeptide as well as epitope formation.
In one embodiment, modification of any of the sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 by a combination of two or more of the modifications of the invention.
In another embodiment, the production of natural and/or synthetic peptidomimetics mimicking the three dimensional structure of an oligopeptide sequence according to invention and/or mimicking the three dimensional structure of a modification of such an oligopeptide according to the invention.
In one embodiment, the preventive or therapeutic use of one or more of the oligopeptides identified as SEQ ID No: 1 through SEQ ID NO: 111 and/or modifications to the invention and/or other peptidomimetics to directly and competitively reduce or block infections by the African Swine virus.
In another embodiment, the preventive or therapeutic use of one or more of the oligopeptides identified as SEQ ID No: 1 through SEQ ID NO: 111 and/or modifications to the invention and/or other peptidomimetics to indirectly reduce or block the metabolic action or interaction of African Swine virus by applying them as vaccines by subcutaneous application or in another acceptable way to stimulate a specific immune response which can partially or completely block infections by the African Swine virus.
In a preferred embodiment, the preventive or therapeutic use of one or more of the oligopeptides identified as SEQ ID No: 1 through SEQ ID NO: 111 and/or modifications to the invention and/or other peptidomimetics to directly and competitively reduce or block immune deficiencies. In yet another preferred embodiment, the preventive or therapeutic use of one or more of the oligopeptides identified as SEQ ID No: 1 through SEQ ID NO: 111 and/or modifications to the invention and/or other peptidomimetics to indirectly reduce or block the metabolic action or interaction of African Swine virus by applying them as vaccines by subcutaneous application or in another acceptable way to stimulate a specific immune response which can partially or completely block immune deficiencies.
In still yet another preferred embodiment, the use of one or more of the oligopeptides identified as SEQ ID No: 1 through SEQ ID NO: 111 and/or modifications to the invention to prevent or treat immune deficiencies in any other medically acceptable way.
In one aspect of the invention, the use of one or more of the oligopeptides identified as SEQ ID No: 1 through SEQ ID NO: 111 and/or modifications to the invention and/or other peptidomimetics for the prevention or therapy of infectious diseases.
In another aspect of the invention, the use of one or more of the oligopeptides identified as SEQ ID No: 1 through SEQ ID NO: 111 and/or modifications to the invention and/or other peptidomimetics for the prevention or therapy of diseases that may turn out to be caused or related to African Swine virus.
In yet another aspect of the invention, the preventive and therapeutic use of one or more of the oligopeptides identified as SEQ ID No: 1 through SEQ ID NO: 111 and/or modifications to the invention and/or peptidomimetics according to claim 1 to 10 where the oligopeptides are coupled to haptens to enhance immune response and thereby therapeutic efficacy.
In still yet another aspect of the invention, the use of one or more of the oligopeptides of claim 1-111 and/or modifications thereof identified as SEQ ID No: 1 through SEQ ID NO: 111 and/or other peptidomimetics of the invention for the production of specific antibodies for the diagnosis of a disease involving African Swine virus or the clinical monitoring of the progression or regression of this disease.
In one preferred embodiment of the invention, the use of one or more of the oligopeptides identified as SEQ ID No: 1 through SEQ ID NO: 111 and/or modifications to the invention and and/or other peptidomimetics for the production of specific antibodies for the diagnosis or the clinical monitoring of the progression or regression of immune deficiencies.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows the antigenicity scores derived from and according to the Hopp-Woods hydrophylicity algorithm for the protein p54, a 183 amino acid long structural protein of the African Swine virus. Since p54 is involved in the pathogenesis of African Swine fever (2), interrupting this pathogenicity-mediating pathway will lead to a decrease or a complete block of infection by this virus.
The relative peaks of this algorithm, defined as amino acid sequence regions of either high hydrophilic characteristics or sequence regions of higher hydrophilic characteristics in relation to adjacent amino acid sequences or in comparison to hydrophobic regions of the protein, represent the likely candidate sequence regions (oligopeptides) serving as epitopes (antigens) for antibody formation. Moreover these defined oligopeptide sequences represent the likely region by which a protein interacts with other proteins and/or biological compounds in an organism, including those interactions that mediate infection or other forms of pathogenicity.
Producing synthetic oligopeptides, corresponding to these algorithm maxima allows the development of preventive and therapeutic agents to control African Swine fever infections. The relative peaks of the Hopp-Woods algorithm for the p54 protein of the African Swine virus selected for this patent application are marked by arrows. The synthetic oligopeptides for the other African Swine fever proteins specified in this disclosure and the claims are selected in an analogous way.
DEETAILED DESCRIPTION OF THE INVENTION
The African Swine virus is a particular virus the pathogenicity of which is largely determined by targeting the immune system of the host and disabling it.
Despite the DNA sequence of African Swine virus having been determined (3), there is currently no effective vaccine available to control African Swine fever as documented in the United Nations Food and Agricultural Organization's field handbook on this disease (4)
The present invention describes the identification and production of preventive and therapeutic agents, which - among others - can be used as vaccines against African Swine fever with the following specific steps being taken:
1. The identification of structural proteins and/or pathogenicity- mediating proteins and/or any other protein from the African Swine virus.
2. The analysis of the amino acid sequence of these proteins using specific algorithms allowing the determination of relative hydrophilic and/or polarity and/or charge and/or surface probability peaks and/or any other method allowing the determination of potential epitopes within these African Swine fever virus proteins. 3. The production of synthetic oligopeptides analogous to the epitope forming oligopeptides identified within the amino acid sequence of the African Swine fever virus proteins. 4. The modification of these synthetic oligopeptides to allow or improve antigencity and the formation of antibodies and/or to block pathogenicity of the African Swine fever virus in any other way by a. adding one or several predetermined amino acids to the selected oligopeptide sequence; b. subtracting one or several predetermined amino acids to the selected oligopeptide sequence; c. replacing one or several predetermined amino acids within the selected oligopeptide sequence; d. changing the linear topology of the selected oligopeptide to a cyclic topology; e. forming a linear chain of covalently bound repeats of the selected oligopeptide sequence; f. forming a cyclic chain of covalently bound repeats of the selected oligopeptide sequence; g. coupling an originally selected and/or modified oligopeptide to one or more haptens; h. to improve antigencity and enhance antibody formation in any other possible way; i. producing natural and/or synthetic peptidomimetics mimicking the three dimensional srtructure of the natural or modified oligopeptide. 5 To conduct in vitro and in vivo tests with the selected oligopeptides and/or peptidomimetics in order to establish their efficacy and efficiency as a therapeutic or diagnostic agents. 6 To identify those originally selected and/or modified synthetic oligopeptides and/or peptidomimetics for therapeutic or diagnostic use that a. display maximum and/or optimum ability to form antibodies against the African Swine virus as potential therapeutic vaccines; b. display maximum and/or optimum competitive inhibition of pathogenicity mediating pathways of the African Swine virus as potential therapeutic agents used for - but not limited to - acute therapeutic treatment of African Swine fever; c. display maximum and/or optimum antigenicity to raise antibodies for the development of tests to diagnose African Swine fever.
77 To use those originally selected and/or modified synthetic oligopeptides and/or peptidomimetics as therapeutic vaccines that display maximum and/or optimum ability to form antibodies against the African Swine virus. 8 To use those originally selected and/or modified synthetic oligopeptides and/or peptidomimetics as therapeutic vaccines that display maximum and/or optimum ability for competitive inhibition of pathogenicity mediating pathways of the African Swine virus as potential therapeutic agents used for - but not limited to - the acute therapeutic treatment of African Swine fever. 9. To use those originally selected and/or modified synthetic oligopeptides and/or peptidomimetics that display maximum and/or optimum antigenicity to be used in the development of diagnostic tests or screening procedures for the African Swine virus.
The current invention also describes the application of the current invention for the diagnosis and treatment of immune deficiency conditions in mammals.
The following are the characteristics of the African Swine Virus:
1. it targets the immune system of the host
2. it has the following morphological features, in particular it structurally and functionally impairs the lymph nodes and other integral parts of the immune system;
3. its hematological changes includes a significant decrease of CD4 and T-cell counts;
4. both viruses share similar clinical findings, namely lymph node swelling, increased susceptibility to infections, and others;
5. it has both an acute and chronic form of infectious states;
6. it is known to display a high frequency of alteration of their genetic sequence in order to escape the host defense system;
7. it is endemic in sub-Saharan Africa and few other regions.
While the African Swine virus has been primarily detected in pigs and certain other animals, antibodies against the African Swine virus have also been found in humans (5). The fact that there was no description of any finding of the African Swine virus in humans may thus be attributable to oversight or a lack of understanding for the significance of African Swine fever virus for the pathogenicity of immune deficiencies in humans. Thus, the inventions described in this patent application can have far reaching implications not only for the control of African Swine fever but also for the control of other immunodeficiency diseases.
The main structural and/or pathogenicity mediating proteins of the African Swine virus are the following:
-Ser-Arg-Pro-Pro-Leu-Ser-Ser-Glu-Ala-Asn-Leu-Tyr-Ala-Lys-Leu-Gln-Asp-His- Ile-Gln-Arg-Gln-Thr-Arg-Pro-Phe- (SEQ ID NO: 1); -Gly-Asp-Lys-Asn-Pro-Val-Gln-His-Ile-Lys-Asp-Tyr-His-Ile-Asp-Ser(SEQ ID NO: 2);
-Ser-Lys-Ala-Lys-Leu-Arg-Val-Ile-Glu-Gly-Ile-Ile-Arg-Ala-(SEQ ID NO: 3); -Phe-Lys-Val-Asp-Thr-Lys-Gln-Pro-Ile-Glu-Asp-Ile-Leu-Lys-Asp-Ile-Lys-Lys- Gln-Leu-Pro-Asp-Pro-Arg-Ala-(SEQ ID NO: 4); -Ala-Glu-Lys-Gln-Glu-Thr-Val-Cys-Lys-Met-(SEQ ID NO: 5); -Gln-Glu-Phe-Ile-Asp-Leu-Gly-Gln-Asp-Lys-Leu-Ile-Asp-Thr-(SEQ ID NO: 6); -Ala-Glu-Lys-Gln-Glu-Thr-Val-Cys-Lys-Met-Ile-Ala-Asp-Ala-Ile-Asn-Gln-Glu- Phe-Ile-Asp-Leu-Gly-Gln-Asp-Lys-Leu-Ile-Asp-Thr-Thr-Asp-Gly-Ala-Ala-Ser-Ile- Cys-Arg-Gln-(SEQ ID NO: 7);
-Leu-Arg-Ala-Glu-Tyr-Leu-Asp-Val-His-Gly-Ser-Ile-Glu-Asn-Thr-Leu-Glu-Asn- Ile-Lys-Leu-(SEQ ID NO: 8);
-Asn-Asp-Ala-Ile-Lys-Gln-Leu-His-Glu-Arg-Met-VaKSEQ ID NO: 9); -Thr-Glu-Val-Thr-Lys-Ala-Ala-Pro-Asn-Glu-Glu-Val-(SEQ ID NO: 10); -Ile-Glu-Ala-Val-Tyr-Arg-Arg-Leu-Leu-Asn-Glu-Gln-Asn-Leu-(SEQ ID NO: 11); -Thr-Gln-Lys-Glu-Leu-Asp-Lys-Leu-Gln-Thr-Asp-Glu-Val-Asp-Ile-(SEQ ID NO:
12); -Leu-Cys-Asn-Leu-Gly-Ile-Ala-Ala-Ser-Val-Ala-Asn-Lys-Ile-Asn-Lys-Ala-Leu-
Gln-Lys-Val-Gly-Leu-Lys-Val-Glu-Gln-Tyr-Leu-Gln-Ser-Lys-Asn-Trp-Ala-Glu- Phe-Asp-Lys-Glu-Leu-Asp-Leu-Lys-Arg-Phe-Ser-Gly-Leu-Val-Ser-Ala-Glu-Asn- Ile-Ala-Glu-Phe-Glu-Lys-Ala-Val-Asn-Leu-Leu-Arg-Gln-Thr-Phe-Asn-Glu-Arg- His-Lys-Ile-Leu-Glu-Asn-Ser-Cys-Ala-(SEQ ID NO: 13); -Asn-Lys-Ile-Asn-Lys-Ala-Leu-Gln-Lys-Val-Gly-Leu-Lys-Val-(SEQ ID NO: 14); -Ser-Lys-Asn-Trp-Ala-Glu-Phe-Asp-Lys-Glu-Leu-Asp-Leu-Lys-Arg-Phe-(SEQ ID NO: 15);
-Ala-Glu-Asn-Ile-Ala-Glu-Phe-Glu-Lys-Ala-Val-Asn-Leu-Leu-Arg-Gln-Thr-Phe- Asn-Glu-Arg-His-Lys-Ile-Leu-Glu-Asn-(SEQ ID NO: 16); -Ala-Lys-Lys-Gly-Gly-Asp-Glu-Glu-Lys-Thr-(SEQ ID NO: 17); -Pro-Leu-Asp-Arg-Arg-Ile-Glu-Ala-Gln-Arg-Leu-Asp-Arg-Lys-His-Ile-(SEQ ID NO: 18);
-Ala-Lys-Lys-Gly-Gly-Asp-Glu-Glu-Lys-Thr-Pro-Leu-Asp-Arg-Arg-Ile-Glu-Ala- Gln-Arg-Leu-Asp-Arg-Lys-His-Glu-(SEQ ID NO: 19); -Asn-Asp-Phe-Leu-Glu-Asn-Val-Lys-Lys-Ile-Gly-Ile-Lys-Leu-Val-Lys-Glu-Ile- (SEQ ID NO: 20);
-Thr-Arg-Leu-Arg-Asp-Ala-Leu-Ser-Arg-Ile-Asn-Asp-Met-(SEQ ID NO: 21); -Ala-Arg-Glu-Glu-Arg-Glu-Thr-Phe-(SEQ ID NO: 22); -Val-Lys-Asn-Val-Leu-Glu-Glu-Gln-Ser-Lys-Ile-Asp-Pro-Asn-Phe-Lys-Asn-(SEQ ID NO: 23);
-Tyr-Asp-Ser-Cys-Ser-Arg-Leu-Leu-Gln-Ile-Ile-Asp-Phe-Tyr-Thr-Asp-Ile-Val- Gln-Lys-Lys-Tyr-Gly-Gly-Gly-Glu-Asp-Cys-Glu-Cys-Thr-Arg-Val-(SEQ ID NO: 24);
-Tyr-Asp-Ser-Cys-Ser-Arg-Leu-Leu-Gln-Ile-Ile-Asp-Phe-Tyr-Thr-Asp-Ile-Val- Gln-Lys-Lys-Tyr-Gly-Gly-Gly-Glu-Asp-Cys-Glu-(SEQ ID NO: 25); -Val-Gln-Lys-Lys-Tyr-Gly-Gly-Gly-Glu-Asp-Cys-Glu-Cys-Thr-Arg-Val-(SEQ ID NO: 26);
-Val-Glu-Glu-Leu-Gly-Leu-Ser-Lys-Ala-Ala-Arg-Ser-Gln-Val-Asp-Leu-Asn-Gln- Ala-IIe- Asn-Thr-Phe-Met-Tyr-Tyr-Tyr-Tyr-Val-Ala-Gln-Ile-Tyr-Ser-Asn-Leu-Thr- His-Asn-Lys-Gln-Glu-Phe-Gln-Ser-Tyr-Glu-Glu-Asn-(SEQ ID NO: 27); -Thr-His-Asn-Lys-Gln-Glu-Phe-Gln-Ser-Tyr-Glu-Glu-Asn-(SEQ ID NO: 28); -Met-Gln-Leu-Asp-Thr-Glu-Lys-Asn-Ala-Arg-Ile-Asn-Ser-Pro-Ala-Val-Asp-Leu- Ala-Arg-Gly-(SEQ ID NO: 29);
-Ala-Gln-Glu-Ala-Asp-Trp-Lys-Ala-Ala-Val-Ser-Ala-Ile-Glu-Leu-Glu-Tyr-Asp-Val- Lys-Arg-Arg-Phe-Tyr-Arg-Ala-Leu-Glu-Gly-Leu-Asp-Leu-(SEQ ID NO: 30); -Leu-Lys-Asn-Ile-Thr-Lys-Thr-Phe-Val-Asn-Asn-Ile-Asp-Ser-(SEQ ID NO: 31); -Leu-Asp-Gly-Val-Arg-Ile-Ile-Gly-Arg-Trp-Phe-Thr-Glu-Ala-Thr-Gly-Asp-Thr- (SEQ ID NO: 32);
-Ala-Glu-Ile-Gln-Gln-Gly-Arg-Ser-Val-Gly-Thr-Leu-Arg-Pro-Val-Arg-Ala-Ser-Gln- Ala-Lys-Asn-Ile-Arg-Asp-Leu-(SEQ ID NO: 33); -Ala-Arg-Ile-Gly-Asp-Met-Leu-Gly-Gly-Glu-Glu-Leu-Arg-Gln-Met-(SEQ ID NO: 34);
-Leu-Lys-Asn-Leu-Asn-Gln-Ser-Glu-Ile-Gly-Gly-Gln-Arg-Val-Ala-Leu-Ala-Arg- Thr-Pro-Glu-Glu-Ala-Ala-Gln-Arg-Val-(SEQ ID NO: 35); -Asn-Asp-Ala-Leu-Ser-Thr-Arg-Trp-Glu-Thr-Glu-Asp-Val-(SEQ ID NO: 36); -Tyr-Asp-Met-Phe-Glu-Arg-Pro-Glu-Pro-Val-Tyr-I_ys-Leu-(SEQ ID NO: 37); -Ala-Asp-Glu-Leu-Glu-Pro-Glu-Val-Ile-Pro-Glu-Ala-Ala-Glu-Leu-Tyr-Phe-Arg- Leu-Pro-Arg-Leu-(SEQ ID NO: 38);
-Phe-Arg-Leu-Pro-Arg-Leu-Ala-Glu-Phe-Tyr-Gln-Lys-Leu-(SEQ ID NO: 39); -Met-Arg-Pro-Ile-Glu-Leu-Ile-Asn-Ile-Gly-Asp-Tyr-Ser-Glu-Thr-Glu-Ile-Arg-Gln- Leu-Ile-Lys-Glu-Ile-(SEQ ID NO: 40);
-Leu-Glu-Tyr-Gly-Glu-Gln-Glu-Ala-Thr-Lys-Lys-Ala-Leu-Ile-His-Phe-Val-Asn- Glu-IIe-(SEQ ID NO: 41);
-Asn-Arg-Arg-Phe-Gly-Val-Ile-Thr-Arg-Thr-Glu-Trp-Glu-Lys-Phe-Gln-Arg-Ile- (SEQ ID NO: 42);
-Gln-Arg-Ile-Val-Gln-Glu-Ala-Arg-Thr-Met-Asn-Asp-Phe-Gly-(SEQ ID NO: 43); -Ser-Gln-Trp-Asp-Leu-Val-Gln-Lys-Phe-Arg-Lys-Gln-Leu-(SEQ ID NO: 44); -Gln-Lys-Phe-Arg-Lys-Gln-Leu-Ser-Glu-Met-Phe-Glu-Asp-Pro-Ser-(SEQ ID NO: 45);
-Gln-Gln-Glu-Leu-Gly-Lys-Val-Ser-Tyr-Gln-Glu-Leu-Ile-Arg-Gln-(SEQ ID NO: 46); -Ile-Asn-Glu-Leu-Lys-Lys-Glu-His-Thr-Asp-Lys-Ile-Gln-Ile-Val-Ser-Lys-Leu- (SEQ ID NO: 47);
-Leu-Lys-Lys-Glu-His-Thr-Asp-Lys-Ile-Gln-Ile-Val-Ser-Lys-Leu-Ile-Gln-Gly-Ser- Glu-Ser-Leu-Ala-Asp-Thr-Asp-Val-Asn-Lys-Ile-(SEQ ID NO: 48); -Phe-Arg-Asn-Asn-Ile-Lys-Gly-Leu-Asp-Leu-Asp-Thr-Ile-Gln-Lys-Ser-(SEQ ID
NO: 49);
-Ile-Glu-Trp-Leu-Arg-Glu-Thr-Gln-Ala-Ala-Asn-Val-Asn-Arg-Ala-(SEQ ID NO:
50);
-Ile-Asp-Trp-Leu-Gly-Arg-Lys-His-Gly-Ala-Ile-Ser-Glu-Ile-(SEQ ID NO: 51);
-Ile-Arg-Asn-Pro-Gly-Leu-Val-Val-Lys-Glu-Asn-Asp-Val-Arg-Leu-Ser-Arg-Val-
(SEQ ID NO: 52);
-Ala-Glu-Gln-Glu-Leu-Ala-Ala-Arg-Tyr-Leu-Val-Asp-Asn-Gln-Arg-Ile-(SEQ ID
NO: 53);
-Phe-Asn-Lys-Met-Val-Gln-Val-Arg-Phe-Pro-Glu-Thr-(SEQ ID NO: 54);
-Ile-Asp-Ser-Leu-Met-Ala-Asp-Thr-Lys-Tyr-Phe-Leu-Asn-Leu-Leu-Arg-Pro-His-
Ile-Asp-Lys-Asn-(SEQ ID NO: 55);
-LeU-Glu-Glu-HiS-LeU-IIe-ASp-LyS-LeU-IIe-LyS-PrO-PrO-ThIr-ASp-Ala-(SEQ ID
NO: 56);
-Leu-Gln-Leu-Arg-Gly-Gly-Val-Gln-Arg-Arg-Asp-Ala-(SEQ ID NO: 57);
-Ser-Glu-Arg-Phe-Glu-Gln-Tyr-Gly-Arg-Val-(SEQ ID NO: 58); -Leu-Gln-Leu-Arg-Gly-Gly-Val-Gln-Arg-Arg-Asp-Ala-Ala-Asn-Ile-Gln-Ile-Asn- Asn-Asn-Pro-Gln-Pro-Ser-Glu-Arg-Phe-Glu-Gln-Tyr-Gly-Arg-Val-(SEQ ID NO: 59);
-Ile-Arg-Thr-Asn-Asn-Ala-Gln-Glu-Glu-Asn-Thr-(SEQ ID NO: 60); -Leu-Arg-Arg-Tyr-Arg-Leu-Tyr-Gly-Ser-Asp-Tyr-(SEQ ID NO: 61); -Ala-Arg-Phe-Tyr-Asp-Ala-Pro-Ser-Gly-Lys-Ile-(SEQ ID NO: 62); -Met-Glu-Leu-Gly-Tyr-Thr-His-Pro-Asp-Leu-Ala-Arg-Asp-Asn-Ile-Ala-Phe-Gly- His-Arg-Gly-Asp-Pro-Thr-Glu-Gln-Ser-(SEQ ID NO: 63); -Leu-Gln-Arg-Leu-Ile-Lys-Asp-Thr-Asn-Arg-Gln-Gly-(SEQ ID NO: 64); -Thr-Glu-Ile-Pro-Ile-Tyr-Leu-Lys-Glu-Asn-Tyr-Arg-Ala-(SEQ ID NO: 65); -Leu-Gln-Arg-Leu-Ile-Lys-Asp-Thr-Asn-Arg-Gln-Gly-Leu-Ser-Gln-His-Leu-Ile- Ser-Thr-Leu-Thr-Glu-Ile-Pro-Ile-Tyr-Leu-Lys-Glu-Asn-Tyr-Arg-Ala-(SEQ ID NO: 66);
-Ser-Asp-Val-Val-Arg-Lys-Arg-Leu-Val-Ala-Val-Ile-Asp-Gly-Ile-Ile-Arg-Gly-(SEQ ID NO: 67);
-Tyr-Leu-Glu-Thr-Glu-Glu-His-Phe-Ile-Gln-Asn-Tyr-Met-Ser-Arg-Tyr-Asn-Lys- Glu-PrO-(SEQ ID NO: 68);
-Tyr-Leu-Arg-Asp-Leu-Arg-Ile-Glu-Asn-Asn-Glu-Val-Tyr-Asp-Pro-Leu-(SEQ ID NO: 69);
-Leu-Glu-Ser-Gly-Ser-Pro-Glu-Phe-Lys-Leu-Leu-Tyr-Gly-Thr-Arg-Lys-Leu-(SEQ ID NO: 70); -Met-Lys-Asn-Tyr-Asn-Glu-Thr-Val-Val-Ala-Arg-Glu-Gln-Ile-Thr-Pro-Thr-Arg- Phe-Glu-His-(SEQ ID NO: 71);
-Ile-Ser-Glu-Asn-Arg-Asp-Asp-Lys-Pro-Ile-(SEQ ID NO: 72); -Leu-Arg-Lys-Thr-Leu-Gln-Asp-Val-Ile-Ser-Phe-Val-Glu-Ser-Ser-Tyr-Gln-Glu- Glu-Gln-IIe-ASn-HiS-IIe-HiS-LyS-IIe-(SEQ ID NO: 73); -Pro-Lys-Gly-Gln-Thr-Arg-Thr-Leu-Gly-Ser-Asn-Arg-Glu-Arg-Glu-Arg-Ile-(SEQ ID NO: 74);
-Tyr-Asp-Tyr-Ser-Phe-Glu-Glu-Ile-Ala-Cys-Leu-Met-Tyr-Gly-Ile-Ser-Ala-Glu- Lys-Val-Arg-Ser-(SEQ ID NO: 75);
-Pro-Asp-Ile-Ala-Glu-Val-Leu-Asn-Ile-Pro-Asn-Arg-Pro-Pro-Met-Asn-Thr-Arg- Glu-Phe-Met-Leu-Lys-Leu-(SEQ ID NO:76);
-Met-Ser-Arg-Ile-Phe-Arg-Gly-Asp-Asn-Ala-Leu-Asn-Met-Gly-Arg-Pro-Lys-Phe- Leu-Ser-Asp-Gln-Ile-Phe-Asn-Lys-Val-(SEQ ID NO: 77); -Ile-Gln-Arg-Gly-Arg-Glu-Gln-Trp-Gly-(SEQ ID NO: 78); -Glu-Tyr-Ile-Asn-Gln-Ala-Leu-His-Glu-Leu-Val-Arg-Thr-Ile-Arg-Ile-Pro-Gln-Lys- Leu-Arg-Val-Leu-Arg-Asn-(SEQ ID NO: 79);
-Ile-Arg-Glu-Gln-Leu-Val-Ser-Met-Arg-Arg-Glu-Val-Glu-Asn-Met-Ile-Gln-Thr- Pro-Glu-Ile-Gln-Asn-Asn-Pro-Thr-Pro-(SEQ ID NO: 80); -Thr-Gln-Gln-Tyr-Arg-Ala-Arg-Val-Asp-Thr-(SEQ ID NO: 81); -His-Pro-Arg-Gln-Ile-Leu-Gln-Thr-Asp-Asp-Glu-Ala-(SEQ ID NO: 82); -Thr-Asp-Leu-Ala-Asn-Asp-Leu-Arg-Thr-Phe-Leu-Glu-Thr-Leu-Glu-Arg-Tyr- (SEQ ID NO: 83); -Gly-Arg-Val-Ala-Arg-Ala-Pro-Val-Arg-Met-Ala-Pro-Arg-Asp-Met-Arg-His-Pro- Ile-(SEQ ID NO: 84);
-Thr-Asp-Leu-Ala-Asn-Asp-Leu-Arg-Thr-Phe-Leu-Glu-Thr-Leu-Glu-Arg-Tyr-Val-
Phe-Asn-Val-Pro-Arg-Trp-Leu-Gly-Pro-Ser-Thr-Gly-Arg-Val-Ala-Arg-Ala-Pro-
Val-Arg-Met-Ala-Pro-Arg-Asp-Met-Arg-His-Pro-Ile-(SEQ ID NO: 85);
-Thr-Glu-Gln-Asn-Arg-Glu-Glu-Gly-Pro-(SEQ ID NO: 86);
-Thr-Glu-Gln-Asn-Arg-Glu-Glu-Gly-Pro-Trp-Ser-Ile-Val-Lys-Gln-Val-Gly-Val-Gly-
Ile-Gln-Lys-Pro-Thr-Leu-Val-Gln-Ile-Gly-Lys-Asp-Arg-Phe-Asp-Thr-Arg-Leu-
(SEQ ID NO: 87);
-Gly-I_ys-Asp-Arg-Phe-Asp-Thr-Arg-I_eu-(SEQ ID NO: 88);
-Ile-Gln-Arg-Leu-Leu-Arg-Leu-Arg-Leu-Asn-Leu-Glu-Leu-Ser-Gln-Phe-Arg-Asn-
(SEQ ID NO: 89);
-Val-Gln-Ile-Gly-Lys-Asp-Arg-Phe-Asp-Thr-Arg-Leu-Ile-Arg-Asn-(SEQ ID NO:
90);
-Ile-Gln-Arg-Leu-Leu-Arg-Leu-Arg-Leu-Asn-Leu-Glu-Leu-Ser-Gln-Phe-Arg-Asn-
(SEQ ID NO: 91);
-Ser-Glu-Thr-Phe-Ser-Asp-Lys-Gln-Tyr-Asp-Ser-Asp-Ile-Arg-Ile-(SEQ ID NO:
92);
-Trp-Glu-Ser-Asp-Leu-Pro-Arg-His-Asn-Arg-Tyr-Ser-Asp-Asn-(SEQ ID NO: 93);
-Asn-Glu-Tyr-Thr-Asn-Ser-Pro-Glu-Lys-Ala-Glu-Lys-Gly-Leu-Gln-Leu-Ser-Asp-
Leu-Arg-Asn-(SEQ ID NO: 94); -Gln-His-Lys-Asn-Ile-Gly-Tyr-Gly-Asp-Ala-Gln-Asp-Leu-Glu-Pro-Tyr-(SEQ ID
NO: 95);
-Gly-Asp-Ala-Gln-Asp-Leu-Glu-Pro-Tyr-Ser-Ser-Ile-Pro-Lys-Asn-Lys-Leu-(SEQ
ID NO: 96);
-Thr-Glu-Asn-Leu-Ile-Arg-Arg-Asn-Val-Val-Arg-Thr-Glu-Lys-Lys-Thr-(SEQ ID
NO: 97);
-Thr-Arg-Phe-Ser-Glu-His-Thr-I_ys-Phe-(SEQ ID NO: 98);
-Tyr-Glu-Asp-Ile-Pro-Lys-Leu-Lys-Thr-Lys-Gly-Thr-Ile-Lys-His-Glu-Gln-His-Leu-
(SEQ ID NO: 99);
-Val-Glu-I_ys-Gly-Ile-Ala-Gly-Arg-Gly-(SEQ ID NO: 100);
-Val-Lys-Pro-Asn-Ile-Glu-Gln-Glu-Leu-Ile-Lys-Ser-(SEQ ID NO: 101);
-Val-Glu-Lys-Gly-Ile-Ala-Gly-Arg-Gly-Ile-Pro-Leu-Gly-Asn-Pro-His-Val-Lys-Pro-
Asn-Ile-Glu-Gln-Glu-Leu-Ile-Lys-Ser-(SEQ ID NO: 102); -Pro-Lys-Asp-Ser-Gln-His-Gly-Arg-Glu-Tyr-Gln-Glu-Phe-Ser-Ala-Asn-Arg-His-
(SEQ ID NO: 103); -Ile-Lys-Pro-Gln-Ile-Leu-Glu-Asp-Ile-(SEQ ID NO: 104);
-Ser-Lys-Arg-Asn-Ser-Gly-Gln-Ala-Glu-Tyr-Phe-Asp-Thr-Ser-Lys-Gln-(SEQ ID
NO: 105);
-Gly-Asp-Ser-Lys-Leu-Asp-Ser-Thr-Phe-Pro-Lys-Asp-(SEQ ID NO: 106);
-Ala-Glu-Lys-Asp-His-Ser-I_eu-Arg-Gly-Asp-Asn-(SEQ ID NO: 107);
-Ser-Ala-Glu-Lys-Asp-His-Ser-Leu-Arg-Gly-Asp-Asn-Ser-Ala-Cys-Cys-Ile-Ser- Asn-Tyr-Ile-Pro-Lys-Tyr-Thr-Gly-Gly-Ile-Gly-Asp-Ser-Lys-Leu-Asp-Ser-Thr- Phe-Pro-Lys-Asp-Phe-Asn-Ala-Ser-Ser-Val-Pro-Leu-Thr-Ser-Ala-Glu-Lys-Asp- His-Ser-Leu-Arg-Gly-Asp-Asn-Ser-Ala-Cys-Cys-Ile-(SEQ ID NO: 108); -Gly-Asp-Ser-Lys-Leu-Asp-Ser-Thr-Phe-Pro-Lys-Asp-Phe-(SEQ ID NO: 109); -Ala-Glu-Lys-Asp-His-Ser-I_eu-Arg-Gly-Asp-Asn-(SEQ ID NO: 110); -Gly-Asp-Ser-Lys-Leu-Asp-Ser-Thr-Phe-Pro-Lys-Asp-Phe-Asn-Ala-Ser-Ser-Val- Pro-Leu-Thr-Ser-Ala-Glu-Lys-Asp-His-Ser-Leu-Arg-Gly-Asp-Asn-(SEQ ID NO: 111).
References cited:
1 Duncan RA et al Idiopathic CD4+ T-lymphocytopenia — four patients with opportunistic infections and no evidence of HIV infection N Engl 1 Med 1993, 328(6) 393-8
2 Rodriguez F et al Characterization and molecular basis of heterogeneity of the African Swine Fever virus envelope protein p54 1 Virol 1994, 68 (11 ) 7244-7252
3 Yanez R1 et al Analysis of the complete nucleotide sequence of African Swine Fever virus Virology 1995, 208 249-278
4 Recognizing African Swine Fever, A Field Manual, UN Food and Agricultural Organization, ISBN 92-5-104471-6
5 Hess WR African Swine Fever A Reassessment Advances in Veterinary Science and Comparative Medicine VoI 25 Cornelius CE, Simpson CF eds Academic Press, New York, 1981 39-69

Claims

WHAT IS CLAIMED IS:
1. Oligopeptides selected from the group consisting of SEQ ID NO: 1 through SEQ ID NO: 111.
2. The oligopeptides according to claim 1 , wherein the sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by omitting one or several predetermined amino residues at the N - terminal end.
3. The oligopeptides according to claim 1 , wherein the sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by omitting one or several predetermined amino acid residues at the C-terminal end.
4. The oligopeptides according to claim 1 , wherein the sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by omitting one or several predetermined amino acid residues at the N-terminal and the C-terminal end.
5. The oligopeptides according to claim 1 , wherein the sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by substituting one or several predetermined amino acid residues within the given sequence without consideration of charge and polarity of the substitution residue.
6. The oligopeptides according to claim 1 , wherein the sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by substituting one or several predetermined of the amino acid residues
7. The oligopeptides according to claim 1 , wherein the sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by omitting one or several predetermined amino acid residues within the given sequence.
8. The oligopeptides according to claim 1 , wherein the sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by repeating the oligopeptides sequence one or more times each of them covalently bound to one or several predetermined oligopeptides repeat(s) with linear topology or other peptidomemetic.
9. The oligopeptides according to claim 1 , wherein the sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by using cyclic oligopeptide topology instead of linear oligopeptide topology or other peptidomemetic.
10. The oligopeptides according to claim 1 , wherein the sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 are modified by repeating the oligopeptide sequence one or more times each of them covalently bound to one or more oligopeptides repeat(s) with cyclic topology or other cyclic peptidomemetic.
11 . The oligopeptides according to claim 1 , wherein the sequences identified as SEQ ID No: 1 through SEQ ID NO: 111 that contain two residues of the amino acid cystein are modified to form disulfide bonds thereby changing the secondary and tertiary structure of the oligopeptide as well as epitope formation.
PCT/US2007/073189 2007-07-10 2007-07-10 African swine virus polypeptides as vaccines and its therapeutic use thereof WO2009008888A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2007/073189 WO2009008888A1 (en) 2007-07-10 2007-07-10 African swine virus polypeptides as vaccines and its therapeutic use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/073189 WO2009008888A1 (en) 2007-07-10 2007-07-10 African swine virus polypeptides as vaccines and its therapeutic use thereof

Publications (2)

Publication Number Publication Date
WO2009008888A1 true WO2009008888A1 (en) 2009-01-15
WO2009008888A8 WO2009008888A8 (en) 2009-07-09

Family

ID=40228878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/073189 WO2009008888A1 (en) 2007-07-10 2007-07-10 African swine virus polypeptides as vaccines and its therapeutic use thereof

Country Status (1)

Country Link
WO (1) WO2009008888A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022500050A (en) * 2018-09-18 2022-01-04 スティヒティング ワーゲニンゲン リサーチ African swine fever virus vaccine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019568A1 (en) * 1994-01-14 1995-07-20 Matthias Rath Hydrophilic signal oligopeptides and methods of therapeutic use
EP0311219B1 (en) * 1987-10-09 1996-08-14 Stichting Centraal Diergeneeskundig Instituut Oligopeptides and their use for diagnostic and vaccination purposes for AIDS and ARC

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0311219B1 (en) * 1987-10-09 1996-08-14 Stichting Centraal Diergeneeskundig Instituut Oligopeptides and their use for diagnostic and vaccination purposes for AIDS and ARC
WO1995019568A1 (en) * 1994-01-14 1995-07-20 Matthias Rath Hydrophilic signal oligopeptides and methods of therapeutic use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE NCBI [O] 29 October 2014 (2014-10-29), "African swine fever virus, complete genome", XP055354954, Database accession no. U18466 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022500050A (en) * 2018-09-18 2022-01-04 スティヒティング ワーゲニンゲン リサーチ African swine fever virus vaccine

Also Published As

Publication number Publication date
WO2009008888A8 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
US20080131449A1 (en) Polypeptides from African Swine Fever virus as vaccines for preventive and therapeutic use
Allen et al. A protective monoclonal antibody targets a site of vulnerability on the surface of Rift Valley fever virus
CN107074912A (en) Influenza virus vaccine and application thereof
US7396531B2 (en) Preventive and therapeutic use of polypeptides from African Swine virus as vaccines
CN101575361B (en) Novel specific polypeptide and application thereof in preparing medicament for diagnosing, preventing and treating severe acute respiratory syndrome caused by coronaviruses
CN101891805B (en) Human enterovirus 71 type specific polypeptide and application thereof
CN103221063A (en) High affinity human antibodies to human cytomegalovirus (CMV) gb protein
O'Brien et al. Vaccination with recombinant adenoviruses expressing Ebola virus glycoprotein elicits protection in the interferon alpha/beta receptor knock-out mouse
CN111556896A (en) Cross immunity antigen vaccine and its preparation method
CN102690327A (en) Enterovirus 71 neutralized epitope polypeptide and application thereof
Kovacs-Nolan et al. Fine mapping of sequential neutralization epitopes on the subunit protein VP8 of human rotavirus
Zhang et al. Development and characterization of monoclonal antibodies against red-spotted grouper nervous necrosis virus and their neutralizing potency in vitro
WO2009008888A1 (en) African swine virus polypeptides as vaccines and its therapeutic use thereof
US11767356B1 (en) Canine parvovirus nanobody CPV-VHH-E3 and application thereof
US20110236393A1 (en) Monoclonal antibody production in b cells and uses therof
CN101134781A (en) Recombinant fusion protein carrying anthrax protective antigens epitope inserted to hepatitis B core antigen protein or its fragment and uses thereof
JP6589159B2 (en) Novel feline morbillivirus strain, inactivated vaccine preparation, and feline morbillivirus infection prevention method
JP7145863B2 (en) Modified HSV gB protein and HSV vaccine containing same
Wang et al. Potent antibodies against immune invasive SARS-CoV-2 Omicron subvariants
CN101380466A (en) Polypeptide vaccine for treating diseased induced by high pathogenic avian influenza virus H5N1
RU2778095C2 (en) Vaccine composition against type a foot-and-mouth disease virus
CN101411866A (en) Polypeptide medicament for treating highly pathogenic bird flu virus H5N1induced disease
CN1258538C (en) Recombinant protein
Ricci Uvinha Recombinant Peptide Subunit Vaccine (COVID-19)
CN116769048A (en) Polymeric molecules, single and multiple structures including the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07799469

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07799469

Country of ref document: EP

Kind code of ref document: A1